Comparative Pharmacology
Head-to-head clinical analysis: ACTIGALL versus CHOLBAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIGALL versus CHOLBAM.
ACTIGALL vs CHOLBAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallstone dissolution agent; reduces cholesterol saturation of bile by decreasing hepatic cholesterol secretion and increasing bile acid pool.
Cholic acid is a primary bile acid that acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist, reducing the synthesis of bile acids from cholesterol via feedback inhibition of the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1). It also improves bile flow and reduces the accumulation of toxic bile acid intermediates.
300 mg orally twice daily, or 8-10 mg/kg/day divided into 2-3 doses.
10-15 mg/kg orally once daily; maximum daily dose 500 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 3–5 days, reflecting enterohepatic circulation and slow turnover of the bile acid pool.
Terminal elimination half-life approximately 3.5-7 hours in patients with primary bile acid synthesis disorders; may be prolonged in severe hepatic impairment.
Primarily fecal (biliary excretion of unchanged drug and metabolites); renal excretion is minimal (<1% of dose as unchanged drug).
Primarily biliary (fecal) excretion as conjugates; less than 5% renal excretion as unchanged drug and metabolites.
Category C
Category C
Bile Acid
Bile Acid